Calcium antagonists and the progression of chronic renal failure

Current Opinion in Nephrology and Hypertension

Volumn 7, Issue 2, 1998, Pages 171-176

  Epstein, Murray ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLENTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GUANFACINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; NIFEDIPINE; TRANDOLAPRIL; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY CIRCULATION; KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC;

EID: 0031906121     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199803000-00005     Document Type: Article

References (34)

1. Renal Data System. USRDS 1994 annual data report. Bethesda. Maryland: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: July 1994.
2. National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group report on hypertension and chronic renal failure. Arch Intern Med 1991; 151:1280-1287.
3. Loutzenhiser R, Epstein M. Renal hemodynamic effects of calcium antagonists. In: Calcium antagonists and the kidney. Epstein M, Loutzenhiser R (editors). Philadelphia: Hanley and Belfus: 1990. pp. 33-75.
4. Hayashi K, Epstein M, Saruta T. Altered myogenic responsiveness of the renal microvasculature in experimental hypertension. J Hypertens 1996; 14:1387-1401. This paper provides an extensive review of renal microvascular alterations in experimental hypertension and the effects of calcium antagonists.
5. Epstein M. Calcium antagonists and the kidney: implications for renal protection. In: Calcium antagonists in clinical medicine. 2nd ed. Epstein M (editor). Philadelphia: Hanley and Bellus: 1997. pp. 433-465.
6. Epstein M. Calcium antagonists and the kidney: future therapeutic perspectives. Am J Kidney Dis 1993; 21 (Suppl 3): 16-25.
7. Tojo A, Kimura K, Matsuoka H, Sugimoto T. Effects of manidipine hydrochloride on the renal microcirculation in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992; 20:895-899.
8. Jacobson HR, Striker GE. Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease. Am J Kidney Dis 1995; 25:103-106.
9. Neuringer JR, Brenner BM. Hemodynamic theory of progressive renal disease: a 10-year update in brief review. Am J Kidney Dis 1993; 22:98-104.
10. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.
11. Cattran DC, Greenwood C, Ritchie S. Long-term benefit of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994; 23:247-254.
12. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression ot chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334:939-945.
13. Epstein M. Calcium antagonists and renal protection. Current status and future perspectives. Arch Intern Med 1992; 152:1573-1584.
14. Epstein M. The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure: focus on fixed-dose combination antihypertensive therapy. Ren Fail 1996; 18:813-832. This paper reviews the renoprotective effects of ACE inhibitors and calcium antagonists and considers why their combination might constitute an attractive renoprotective intervention.
15. Epstein M, Loutzenhiser R. Potential applicability of calcium antagonists as renal protective agents. In: Calcium antagonists and the kidney. Epstein M, Loutzenhiser R (editors). Philadelphia: Hanley and Belfus; 1990. pp. 275-298.
16. Harris DCH, Hammond WS, Burke TJ, Schrier RW. Verapamil protects against progression of experimental chronic renal failure. Kidney Int 1987; 31:41-46.
17. Goligorsky MS, Chaimovits C, Rapoport J, Goldstein J, Kol R. Calcium metabolism in uremic nephrocalcinosis: preventive effects of verapamil. Kidney Int 1985; 27:774-779.
18. Jackson B, Johnston Cl. The contribution of systemic hypertension to progression of chronic renal failure in the rat remnant kidney: effect of treatment with an angiotensin converting enzyme inhibitor or a calcium inhibitor. J Hypertens 1988; 6:495-501.
19. Brunner FP, Thiel G, Hermle M, Bock HA, Mihatsch MJ. Long-term enalapril and verapamil in rats with reduced renal mass. Kidney Int 1989; 36:969-977.
20. Tolins JP, Raij L. Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. Hypertension 1990; 16:452-461.
21. Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995; 96:793-800.
22. Griffin K, Picken M, Bidani A. Radiotelemetric BP monitoring, antihypertenisves and glomeruloprotection in remnant kidney model. Kidney Int 1994; 46:1010-1018.
23. Bidani A, Griffin KA. Calcium channel blockers and renal protection: is there an optimal dose? J Clin Lab Med 1995; 125:553-555.
24. Zucchelli P, Zuccalà A, Borghi M, Fusaroli M, Sasdelli M, Stallone C. et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42:452-458.
25. Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45:216-222.
26. Rossing P, Tarnow L, Boelskifter S, Jensen BR, Nielsen FS, Parving H-H. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997; 46:481-487. This study compared the renoprotective effects of an ACE inhibitor with those of a dihydropyridine calcium antagonist.
27. Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated metaanalysis. Nephrol Dial Transplant 1995; 10 (Suppl 9):39-45.
28. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood pressure lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10:1963-1974.
29. Lash JP, Bakris GL. Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol Dial Transplant 1995; 10 (Suppl 9):56-62.
30. Amann K, Törnig J, Nichols C. Zeier M, Mall G, Ritz E. Effect of ACE inhibitors, calcium channel blockers and their combination on renal and extrarenal structures in renal failure. Nephrol Dial Transplant 1995; 10 (Suppl 9):33-38
31. Brown S, Walton C, Crawford P, Bakris GL. Long term effects of different antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993; 43:1210-1218.
32. Munter K, Hergenröder S, Jochims K, Kirchengast M. Individual and combined effects of verapamil or trandolapril on glomeruloprotection in the stroke prone rat. J Am Soc Nephrol 1996; 7:681-686.
33. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992; 41:912-919.
34. Bakris GL, Weir MR, DeQuattro V, Rosendorff C, MacMahon G. Renal hemodynamic and antiproteinuric response to an ACE inhibitor, trandolapril or calcium antagonist, verapamil, alone or in fixed dose combination in patients with diabetic nephropathy: a randomized multicentered study [abstract], J Am Soc Nephrol 1996; 7:1546A.